{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:10:57Z","timestamp":1753891857903,"version":"3.41.2"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Clear cell renal cell carcinoma (ccRCC) is the most prevalent and lethal subtype of renal cell carcinoma (RCC), characterized by a poor prognosis and a high likelihood of distant metastasis. Nonetheless, metastasis of ccRCC to the tongue remains rare. Diagnosing and planning treatment for patients who initially present with tongue metastasis can be particularly challenging, as few cases have been reported in the literature. We present a case of a 62-year-old man who presented with a painful lump on the right anterior border of his tongue. Histological examination revealed lobulated and nested epithelial cell clusters with moderate dysplasia and frequent mitotic figures within the lamina propria. Immunohistochemistry showed positivity for vimentin, CD10, PAX-8, and epithelial membrane antigen (EMA), but negativity for PAX-2, calponin, S-100 protein, periodic acid-Schiff with diastase (PAS-D), P63, P40, and CK7, confirming the diagnosis of ccRCC metastasis to the tongue. After comprehensive evaluation and multidisciplinary team consultation, the patient underwent cytoreductive nephrectomy (CN), metastasectomy, and targeted therapy. According to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, the patient maintained stable disease (SD) during systemic treatment. Unfortunately, treatment was discontinued due to adverse drug reactions, and the patient was transitioned to palliative care. His disease progressed to progressive disease (PD), and he ultimately succumbed to systemic infection, with a progression-free survival (PFS) of approximately 15 months. This case highlights the urgent need for improved therapeutic strategies to manage symptoms and prolong survival in patients with this rare metastatic presentation.<\/jats:p>","DOI":"10.3389\/fonc.2024.1473211","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T05:15:54Z","timestamp":1737954954000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case report: Tongue metastasis as an initial sign of clear cell renal cell carcinoma and its prognosis"],"prefix":"10.3389","volume":"14","author":[{"given":"Shuo","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bowen","family":"Weng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sichuan","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.02.008","article-title":"Single-cell deconvolution of a specific Malignant cell population as a poor prognostic biomarker in low-risk clear cell renal cell carcinoma patients","volume":"83","author":"Saout","year":"2023","journal-title":"Eur Urol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr362","article-title":"Distribution of metastatic sites in renal cell carcinoma: a population-based analysis","volume":"23","author":"Bianchi","year":"2012","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s12105-014-0591-z","article-title":"Metastatic tumors to the jaws and mouth","volume":"8","author":"Hirshberg","year":"2014","journal-title":"Consult Pathol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"01455613231226038","DOI":"10.1177\/01455613231226038","article-title":"Tongue metastasis from renal cell carcinoma: A rare case presentation","author":"Kweon","year":"2024","journal-title":"Ear Nose Throat J"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.05.030","article-title":"A U.S. Food and drug administration\u2013pooled analysis of frontline combination treatment survival benefits by risk groups in metastatic renal cell carcinoma","volume":"84","author":"Lee","year":"2023","journal-title":"Eur Urol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s12105-023-01588-0","article-title":"Clinicopathological features of metastasis to the oral and maxillofacial region\u2014Multicenter study","volume":"17","author":"Kirschnick","year":"2023","journal-title":"Head Neck Pathol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1186\/s13256-017-1470-5","article-title":"Lingual metastasis as an initial presentation of renal cell carcinoma: a case report","volume":"11","author":"Raiss","year":"2017","journal-title":"J Med Case Rep"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.tripleo.2009.12.006","article-title":"Metastatic renal cell carcinoma to the oral cavity and clear cell mucoepidermoid carcinoma: comparative clinicopathologic and immunohistochemical study","volume":"109","author":"Pires","year":"2010","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/PAP.0b013e3181f89400","article-title":"The use of immunohistochemistry in the diagnosis of metastatic clear cell renal cell carcinoma: A review of PAX-8, PAX-2, hKIM-1, RCCma, and CD10","volume":"17","author":"Sangoi","year":"2010","journal-title":"Adv Anat Pathol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s12105-022-01518-6","article-title":"Top 10 clear cell head and neck lesions to contemplate","volume":"17","author":"Cipriani","year":"2023","journal-title":"Head Neck Pathol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e318299f12e","article-title":"Renal tumors","volume":"37","author":"Tan","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"92","DOI":"10.5858\/2010-0478-RAR.1","article-title":"Immunohistochemical diagnosis of renal neoplasms","volume":"135","author":"Truong","year":"2011","journal-title":"Arch Pathol Lab Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.eururo.2022.03.006","article-title":"European association of urology guidelines on renal cell carcinoma: the 2022 update","volume":"82","author":"Ljungberg","year":"2022","journal-title":"Eur Urol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.7931","article-title":"Survival analyses of patients with metastatic renal cancer treated with targeted therapy with or without cytoreductive nephrectomy: A national cancer data base study","volume":"34","author":"Hanna","year":"2016","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.09.016","article-title":"Systematic review of the role of cytoreductive nephrectomy in the targeted therapy era and beyond: an individualized approach to metastatic renal cell carcinoma","volume":"75","author":"Bhindi","year":"2019","journal-title":"Eur Urol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s12105-022-01451-8","article-title":"Metastatic tumors to the oral soft tissues and jawbones: A retrospective analysis of 40 cases and review of the literature","volume":"16","author":"Ho","year":"2022","journal-title":"Consult Pathol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2017-0733","article-title":"Efficacy and safety of first-line sunitinib in Chinese patients with metastatic renal cell carcinoma","volume":"14","author":"Qin","year":"2018","journal-title":"Future Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.3108","article-title":"Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study","volume":"35","author":"Yan","year":"2024","journal-title":"Ann Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1473211\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T05:15:58Z","timestamp":1737954958000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1473211\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,27]]},"references-count":20,"alternative-id":["10.3389\/fonc.2024.1473211"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1473211","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2025,1,27]]},"article-number":"1473211"}}